Recent findings from a multicenter retrospective study showed that children with RASopathies and severe HCM treated with a MAPK kinase (MEK) inhibitor (trametinib) with compassionate/off-label use had significantly reduced morbidity and mortality and improved clinical status compared to those treated with standard care, with manageable side effects [100]. Here, MAP2K7 is linked to RASopathy.